Racial difference in mortality among U.S. veterans with HCV/HIV coinfection

American Journal of Gastroenterology

Volumn 101, Issue 4, 2006, Pages 760-767

  Merriman, Nathan A ^a   Porter, Steven B ^a   Brensinger, Colleen M ^b   Reddy, K Rajender ^a   Chang, Kyong Mi ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Center for Clinical Epidemiology and Biostatistics   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOLISM; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RACE DIFFERENCE; UNITED STATES; VETERAN; VIREMIA;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALCOHOLISM; CD4 LYMPHOCYTE COUNT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; UNITED STATES; VETERANS; VIRAL LOAD;

EID: 33645455934     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00531.x     Document Type: Article

References (41)

1. Liang TJ Rehermann B Seeff LB et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000 132 296 305.
2. Bruno R Sacchi P Puoti M et al. HCV chronic hepatitis in patients with HIV: Clinical management issues. Am J Gastroenterol 2002 97 1598 606.
3. Di Martino V Rufat P Boyer N et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001 34 1193 9.
4. Bica I McGovern B Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001 32 492 7.
5. Monga HK Rodriguez-Barradas MC Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001 33 240 7.
6. Mohsen AH Easterbrook PJ Taylor C et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003 52 1035 40.
7. Benhamou Y Bochet M Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999 30 1054 8.
8. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003 23 183 94.
9. Nunez M Lana R Mendoza JL et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001 27 426 31.
10. Daar ES Lynn H Donfield S et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001 183 589 95.
11. Greub G Ledergerber B Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000 356 1800 5.
12. Lesens O Deschenes M Steben M et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999 179 1254 8.
13. Dorrucci M Pezzotti P Phillips AN et al. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995 172 1503 8.
14. Sulkowski MS Moore RD Mehta SH et al. Hepatitis C and progression of HIV disease. JAMA 2002 288 199 206.
15. Thomas DL Shih JW Alter HJ et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996 174 690 5.
16. Eyster ME Fried MW Di Bisceglie AM et al. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994 84 1020 3.
17. Soto B Sanchez-Quijano A Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997 26 1 5.
18. Bonacini M Lin HJ Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001 26 340 4.
19. Bonacini M Govindarajan S Blatt LM et al. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999 6 203 8.
20. Sherman KE O'Brien J Gutierrez AG et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993 31 2679 82.
21. Cribier B Rey D Schmitt C et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995 9 1131 6.
22. Piasecki BA Lewis JD Reddy KR et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004 40 892 9.
23. Rehermann B. Cellular immune response to the hepatitis C virus. J Viral Hepat 1999 6 Suppl 1 31 5.
24. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2003 7 89 105.
25. Graham CS Baden LR Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001 33 562 9.
26. Eyster ME Diamondstone LS Lien JM et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993 6 602 10.
27. Roudot-Thoraval F Bastie A Pawlotsky JM et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997 26 485 90.
28. Rockstroh JK Spengler U Sudhop T et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996 91 2563 8.
29. Torriani FJ Rodriguez-Torres M Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 438 50.
30. Chung RT Andersen J Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004 351 451 9.
31. Carrat F Bani-Sadr F Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004 292 2839 48.
32. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis 2004 38 Suppl 2 S98 103.
33. Sugimoto K Stadanlick J Ikeda F et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003 37 590 9.
34. Wiley TE Brown J Chan J. Hepatitis C infection in African Americans: Its natural history and histological progression. Am J Gastroenterol 2002 97 700 706.
35. Aceti A Pasquazzi C Zechini B et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002 29 41 8.
36. den Brinker M Wit FW Wertheim-van Dillen PM et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000 14 2895 902.
37. Monforte Ade A Bugarini R Pezzotti P et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001 28 114 23.
38. Sugimoto K Ikeda F Stadanlick J et al. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex-vivo in persistent HCV infection. Hepatology 2003 38 1437 48.
39. Guidotti LG Chisari FV. Cytokine-induced viral purging - Role in viral pathogenesis. Curr Opin Microbiol 1999 2 388 91.
40. Liaw YF Yeh CT Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000 95 2978 80.
41. Sjogren MH. Preventing acute liver disease in patients with chronic liver disease. Hepatology 1998 27 887 8.